Form 4: FATE Therapeutics Director Michael Lee Granted 55,000 Stock Options

FATE Therapeutics Inc. director Michael Lee was granted 55,000 stock options with an exercise price of $1.32, vesting by May 2026, as compensation for his board service and held on behalf of Redmile Group, LLC.

Summary

• Michael Lee, a Director and 10% owner of FATE Therapeutics Inc. (FATE), was granted 55,000 stock options.
• The options have an exercise price of $1.32 per share and an expiration date of May 29, 2035.
• The transaction date for the grant was May 29, 2025.
• The options will vest in full upon the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on Mr. Lee's continued service on the board.
• Mr. Lee holds these options as a nominee for Redmile Group, LLC, and has assigned all economic, pecuniary, and voting rights to Redmile.
• Both Mr. Lee and Redmile Group, LLC, along with its principal Jeremy Green, disclaim beneficial ownership of the options except to the extent of their pecuniary interest.
• Redmile and Mr. Green are considered directors by deputization for Section 16 purposes due to Mr. Lee's board representation of Redmile.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) to a director, which is generally neutral but can be seen as slightly positive due to interest alignment. There are no overtly negative or positive financial results or strategic announcements.

Positives

• The grant of stock options to Director Michael Lee aligns his interests with those of shareholders, as the options gain value if the stock price increases.
• The option grant serves as compensation for Mr. Lee's continued service on the board of directors, ensuring ongoing leadership and strategic input.

Negatives

• The exercise price of $1.32 is relatively low, which could imply a significant potential dilution if the stock price rises substantially above this level and all options are exercised.
• The disclaiming of beneficial ownership by Mr. Lee, Redmile Group, LLC, and Jeremy Green, while standard for nominee holdings, adds a layer of complexity to direct ownership transparency.

Risks

• Potential dilution of existing shareholder value if the 55,000 stock options are exercised, increasing the total number of outstanding shares.

Management Comments

• "The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer."
• "Mr. Lee, a managing director of Redmile Group, LLC ('Redmile'), was elected to the board of the Issuer as a representative of Redmile and its affiliates."
• "Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile."
• "Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."
• "The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."
• "As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."

Industry Context

The granting of stock options to board members is a common practice in the biotechnology and pharmaceutical industries, including for companies like FATE Therapeutics, to incentivize long-term commitment and align director interests with shareholder value creation. This particular grant reflects standard compensation for board service, especially for directors representing significant institutional investors like Redmile Group.

Comparison to Industry Standards

• The grant of 55,000 stock options to a director is within the typical range for non-employee director compensation in the biotechnology sector, though the specific value depends on the company's market capitalization and compensation philosophy.
• The vesting schedule (one year or next annual meeting) is a common practice to ensure continued service and align incentives over a reasonable period.
• The structure where a director holds options as a nominee for an investment firm (Redmile Group) is standard for directors appointed to represent a significant shareholder's interest, ensuring the firm's economic and voting rights are maintained.

Corporate Governance

Related Party Transactions

• The stock option grant to Michael Lee is considered a related party transaction, as he is a director and represents Redmile Group, LLC, a significant shareholder.
• Mr. Lee holds the options as a nominee for Redmile Group, LLC, and has assigned all economic, pecuniary, and voting rights to Redmile, indicating a transaction between the company and an entity related to a director.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options; alignment of director's interests with shareholder value creation.
• Management/Board: Standard compensation for board service, incentivizing continued engagement and strategic oversight.

Next Steps

• Continued service of Michael Lee on the board of directors of FATE Therapeutics Inc.
• Vesting of the 55,000 stock options upon the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

FATE Therapeutics, FATE, SEC Form 4, Stock Option Grant, Director Compensation, Michael Lee, Redmile Group, Insider Trading, Beneficial Ownership, Equity Compensation, Corporate Governance